艾博特医疗器械治疗心律, 在新研究中成功率为87%. Abbott medical devices treat heart rhythms with 87% success in new study.

艾博特在一次医学会议上展示了新的数据, 其脉冲场消化和导电系统节奏技术成功治疗心律异常. Abbott presented new data at a medical conference showing its pulsed field ablation and conduction system pacing technologies successfully treat abnormal heart rhythms. 六个月的TactiFlex Duo导管研究显示,87% 的患者没有心律失常,安全率高. A six-month study of the TactiFlex Duo catheter showed 87% of patients were free from arrhythmias with a high safety rate. 此外,Volt PFA系统和CSP研究线索的数据显示在节奏调控和除方面取得了很大的成功,支持阿博特的监管努力. Additionally, data on the Volt PFA System and investigational CSP leads demonstrated strong success in pacing and defibrillation, supporting Abbott's regulatory efforts.